Fluorescent Dyes for Enhancing Fingerprints

Life Sciences

University: University of St Andrews

Sector(s): Life Sciences

About Opportunity:

Our technology provides a universal solution to enhance fingerprints on all surfaces, including wet and porous ones.  The enhancement is performed by dyeing them with a fluorescent reagent.  The chemicals are safe, non-toxic, clean and easy to handle.  The colour of the fluorescence can be tuned for optimal contrast of the fingerprint with the surface.  Moreover, after application of our dyes, the fingerprints are stabilised, and robust in handling.

Key Benefits:

• The dyes work on all surfaces, including 'difficult' ones (wet, porous)
• The chemicals are safe, non-toxic, easy to handle
• The colour of the enhanced fingerprints can be tuned for optimal contrast with the substrate
• The dyes stabilise the fingerprints

Applications:

• Fingerprint enhancement in forensic laboratories
• In-field and scene-of-crime fingerprint enhancement

IP Status: The technology is subject to granted patents in the USA, Japan, UK, France and Germany (see US 8,377,714)

St Andrews University would be happy to discuss this technology transfer opportunity.  Please use the enquiry form below to contact us.

Enquiry

• 

  Lab in a Pill

  Scientists at the University of Glasgow have pioneered a new sensor technology, Lab-in-a-Pill, that could have major impact on the cost and effectiveness of bowel cancer treatment.

  Expires: 23 March 2018Created: 24 July 2012
• 

  Thermoelectric Sensor

  The Thermoelectric Sensor technology is a Nano-Calorimetric Sensor which measures very small changes in temperature. The IP provides a route to making the most sensitive calorimetric measurements (with a resolution of 0.1 mK).

  Expires: 23 March 2018Created: 24 July 2012
• 

  Parkinson's Disease Model

  The University of Glasgow is offering an exciting new model for the evaluation of new treatments for Parkinsons disease

  Expires: 23 March 2018Created: 24 July 2012
• 

  Combination Treatment for MRSA Nasal Carriage and MRSA-infected Wounds

  The new treatment is a combination of a peptide (ranalexin) with bacteria cell wall-digesting protein (lysostaphin), which specifically targets and kills Staphylococcus aureus, including MRSA.

  Expires: 08 May 2018Created: 27 September 2012
• 

  Synergistic antifungal combination

  Candida species are a major cause of catheter-related nosocomial bloodstream infections. We have identified that the combination of an echinocandin antifungal with certain antimicrobial peptides results in potent, synergistic inhibition of yeast pathogens in vitro, so offering a potential combinatio...

  Expires: 08 May 2018Created: 21 August 2012